RT Journal Article
SR Electronic
T1 Association between Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Exposure and Intraocular Pressure Change
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.06.24306943
DO 10.1101/2024.05.06.24306943
A1 Hallaj, Shahin
A1 Halfpenny, William
A1 Chuter, Benton G.
A1 Weinreb, Robert N.
A1 Baxter, Sally L.
A1 Cui, Qi N.
YR 2024
UL http://medrxiv.org/content/early/2024/05/06/2024.05.06.24306943.abstract
AB Objective This study aims to provide data on the effects of glucagon-like peptide 1 receptor (GLP-1R) agonists on intraocular pressure (IOP).Design Retrospective cohort study.Subjects, Participants, and/or Controls 1247 glaucoma surgery and treatment naïve eyes of 626 patients who were initiated on GLP-1R agonists compared to 1083 glaucoma surgery and treatment naïve eyes of 547 patients who were initiated on other oral antidiabetics.Methods, Intervention, or Testing The University of California Health Data Warehouse was queried for patients exposed to GLP-1R agonists or other oral antidiabetics. Index date was defined as the date of first exposure to the medication. Eyes with at least one pre-exposure and one post-exposure tonometry record within 365 days of the index date were included in the analysis. Clinical and laboratory data elements were extracted from the database. Eyes were censored from the analysis upon exposure to glaucoma hypotensive medication or glaucoma surgery. ΔIOP was analyzed using a paired t-test. Regression analysis was conducted using generalized estimating equations (GEE) accounting for inter-eye correlation. Sensitivity analyses were performed to assess the robustness of the findings.Main Outcome Measures Primary outcome measure was ΔIOP after exposure to the medication.Results The median age of all included subjects was 66.2 years [IQR=18.3]; 607 (51.7%) were female, and 667 (56.9%) were Caucasian. Median pre-exposure IOP, HbA1c, and BMI were 15.2 mmHg [IQR=3.8], 7.5 [IQR=2.4], and 29.8 [IQR=9.4], respectively. 776 individuals (66.1%) had diabetes, with the median number of active oral antidiabetics being 1.0 [IQR=1.0], and 441 (37.5%) being insulin users. Several pre-exposure characteristics significantly differed between the GLP-1R agonist and the control group. The mean ΔIOP was -0.4±2.8 mmHg (paired t-test p<0.001) and -0.2±3.3 mmHg (paired t-test p = 0.297) in the GLP-1R agonist and other antidiabetics groups, respectively. Pre-exposure IOP was the only independent predictor of ΔIOP in multivariable GEE. Sensitivity analyses yielded similar results.Conclusions Although GLP-1R agonists were significantly associated with a decrease in IOP in the paired analysis, they were not associated with ΔIOP in multivariable GEE. Moreover, the difference between the ΔIOP in the two groups was small. Future prospective studies following a standardized dose and delivery method may provide further insights.Competing Interest StatementDr. Baxter reports consulting fees from Topcon and equipment support from Topcon and Optomed outside the submitted work. Dr. Cui reports a provisional patent application related to the topic of this study (publication number: US20220193201A1). SH, WH, and BGC: None. Dr. Weinreb reports consulting fees from Abbvie, Alcon, Balance, Editas, Eyenovia, iSTAR Medical, Nicox, and Topcon outside the submitted work. He also has stock options from Balance, Eyenovia, Iantrek, Implandata,and Toku outside the submitted work and intellectual property licensed from UCSD to Toromedes outside the submitted work.Funding StatementThis study is supported by the Unrestricted Grants from Research to Prevent Blindness (New York, NY), The Glaucoma Foundation, UPenn's Vision Research Center, and the following grants from the National Institutes of Health and National Eye Institute: OT2OD032644, DP5OD029610, R01EY034115, P30EY001583, and P30EY022589.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of California San Diego Institutional Review Board, which also granted a waiver of informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData availability is controlled by UCOP and not released publicly to preserve privacy of patients. Researchers within the University of California system can contact the relevant party on the link provided below. https://www.ucop.edu/uc-health/departments/center-for-data-driven-insights-and-innovations-cdi2.html